June 6th 2011
Continuation maintenance with pemetrexed (Alimta) improves progression-free survival in patients with advanced nonsquamous non–small cell lung cancer
Dr. Wolchok from Memorial Sloan-Kettering Cancer Center Describes the Immunotherapy Ipilimumab
Dr. Kris From Memorial Sloan-Kettering Cancer Center on the Use of Genetic Testing in Lung Cancer
June 5th 2011
The combination of the MEK inhibitor GSK212 and the oral BRAF inhibitor GSK436 resulted in anti-tumor activity in patients with advanced melanoma
Dr. Katherine Virgo from the American Cancer Society Discusses Survivorship Care Training & Policies
Dr. Axel Hoos from Bristol Myers-Squib on the Patients That Respond to Ipilimumab
Dr. Paul Chapman from Memorial Sloan-Kettering Cancer Center Describes the Side Effects of Vemurafenib
Apostolia M. Tsimberidou, MD, PhD, from MD Anderson Cancer Center discusses improving cancer care.
Dr. Cella from Northwestern University Feinberg School of Medicine on Patient Assessment Reference Scores
Taking a page from breast cancer treatment, clinicians managing lung cancer patients can now detect mutations that drive the development of lung cancer
Metastatic breast cancer patients with demonstrated disease progression after taxane therapy face an uphill battle in fighting their disease.
Prostate cancer research lacks surrogate biomarkers for survival that could hasten the study and approval of new medications.
Radiation therapy directed to the regional lymph nodes of women with early-stage breast cancer reduced distant disease recurrence
June 4th 2011
Amonafide+Cytarabine may not be effective for secondary acute myeloid leukemia, according to ACCEDE trial data
High doses of methotrexate increases EFS for children and young adults
Matching patients with targeted therapies based on molecular profile results in superior clinical outcomes
Dr. Heikki Joensuu from the Helsinki University Central Hospital Summarizes the Imatinib for High-Risk high-risk gastrointestinal stromal tumors (GIST) Trial
Tim Turnham the Executive Director of the Melanoma Research Foundation Discusses Melanoma Treatment Advances
May 19th 2011
Oncology specialists, biopharmaceutical analysts and investors all await the latest research news from the upcoming ASCO annual meeting
May 18th 2011
A genetic analysis resulted in the discovery of the first predictive biomarker for taxane-induced peripheral neuropathy